AstraZeneca: anti-lung cancer drug gets fast FDA review.
(CercleFinance.com) - US health regulators granted a priority review status for AstraZeneca's new lung cancer drug Imfinzi, which will speed up the treatment's route to market.
AstraZeneca and its biologics research and development unit MedImmune said that the FDA has accepted a supplemental biologics license application for the treatment of patients with locally advanced (stage III) unresectable non-small cell lung cancer (NSCLC).
The FDA's decision covers patients whose disease has not progressed following platinum-based chemoradiation therapy.
A human monoclonal antibody, Imfinzi counters the tumour's immune-evading tactics and inducing an immune response.
Plus, AstraZeneca and Hong-Kong based partner Chi-Med said savolitinib showed encouraging clinical activity in second-line EGFR mutation-positive lung cancer with MET-amplification.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
AstraZeneca and its biologics research and development unit MedImmune said that the FDA has accepted a supplemental biologics license application for the treatment of patients with locally advanced (stage III) unresectable non-small cell lung cancer (NSCLC).
The FDA's decision covers patients whose disease has not progressed following platinum-based chemoradiation therapy.
A human monoclonal antibody, Imfinzi counters the tumour's immune-evading tactics and inducing an immune response.
Plus, AstraZeneca and Hong-Kong based partner Chi-Med said savolitinib showed encouraging clinical activity in second-line EGFR mutation-positive lung cancer with MET-amplification.
Copyright (c) 2017 CercleFinance.com. All rights reserved.